{"DataElement":{"publicId":"58198","version":"5","preferredName":"Immunophenotype Type","preferredDefinition":"The description of the immunophenotype.","longName":"IMPHENO_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2014673","version":"1","preferredName":"Immunophenotype Description","preferredDefinition":"the type and relative concentrations of various white blood cell populations in blood (NCI).","longName":"IMPHENO_DESC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177104","version":"1","preferredName":"Immunophenotype","preferredDefinition":"Immunophenotype is the characterization of a set of cells according to the antigens expressed.","longName":"Immunophenotype","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Immunophenotype","conceptCode":"C20072","definition":"The characterization of a set of cells according to the antigens expressed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A7E-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177536","version":"1","preferredName":"Description ","preferredDefinition":"Description; a statement that represents something in words.","longName":"Description","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Description","conceptCode":"C25365","definition":"A written or verbal account, representation, statement, or explanation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-51C1-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC9E2131-F0B7-05D7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-05-01","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-05-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2015280","version":"3.1","preferredName":"Immunophenotype Type","preferredDefinition":"the description of the immunophenotype.","longName":"IMPHENO_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IgM decreased","valueDescription":"Reduced IgM","ValueMeaning":{"publicId":"7519132","version":"1","preferredName":"Reduced IgM","longName":"7519132","preferredDefinition":"Made less in size or amount or degree.: The major immunoglobulin secreted during a primary immune response.  IgM binds with low affinity but high avidity (multiple binding sites) because it not only occurs as monomers but also as pentamers and hexamers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reduced","conceptCode":"C25640","definition":"Made less in size or amount or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"IgM","conceptCode":"C569","definition":"The major immunoglobulin secreted during a primary immune response.  IgM binds with low affinity but high avidity (multiple binding sites) because it not only occurs as monomers but also as pentamers and hexamers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56E9265-6B1E-60A8-E053-4EBD850A2CAD","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56E9265-6B37-60A8-E053-4EBD850A2CAD","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"IgG decreased","valueDescription":"Reduced IgG","ValueMeaning":{"publicId":"7519133","version":"1","preferredName":"Reduced IgG","longName":"7519133","preferredDefinition":"Made less in size or amount or degree.: An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reduced","conceptCode":"C25640","definition":"Made less in size or amount or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"IgG","conceptCode":"C568","definition":"An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56E9265-6B44-60A8-E053-4EBD850A2CAD","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56E9265-6B5D-60A8-E053-4EBD850A2CAD","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"IgA decreased","valueDescription":"Reduced IgA","ValueMeaning":{"publicId":"7519134","version":"1","preferredName":"Reduced IgA","longName":"7519134","preferredDefinition":"Made less in size or amount or degree.: IgA is the immunoglobulin subclass that is associated with antibody-mediated mucosal immunity.  It is secreted as dimers into the mucosa and is the most effective isotype at fixing complement by the alternative pathway, even though it lacks the ability to fix complement by the classical pathway. There are two subtypes in the human - IgA1 and IgA2.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reduced","conceptCode":"C25640","definition":"Made less in size or amount or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"IgA","conceptCode":"C565","definition":"IgA is the immunoglobulin subclass that is associated with antibody-mediated mucosal immunity.  It is secreted as dimers into the mucosa and is the most effective isotype at fixing complement by the alternative pathway, even though it lacks the ability to fix complement by the classical pathway. There are two subtypes in the human - IgA1 and IgA2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56E9265-6B6A-60A8-E053-4EBD850A2CAD","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56E9265-6B83-60A8-E053-4EBD850A2CAD","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"NK decreased","valueDescription":"Reduced Natural Killer Cell","ValueMeaning":{"publicId":"7519135","version":"1","preferredName":"Reduced Natural Killer Cell","longName":"7519135","preferredDefinition":"Made less in size or amount or degree.: A type of immune cell that has granules (small particles) with enzymes that can kill tumor cells or cells infected with a virus. A natural killer cell is a type of white blood cell.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reduced","conceptCode":"C25640","definition":"Made less in size or amount or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Natural Killer Cell","conceptCode":"C12536","definition":"Natural killer cells are cells that resemble large granular lymphocytes.  They do not express markers of either T or B cell lineage. They are positive for CD16, CD56, and CD 94.  These cells do possess Fc receptors for IgG and can kill target cells using antibody-dependent cell-mediated cytotoxicity. They can also use perforin to kill cells in the absence of antibody and killing may occur without previous sensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56E9265-6B90-60A8-E053-4EBD850A2CAD","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56E9265-6BA9-60A8-E053-4EBD850A2CAD","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Neutropenia","valueDescription":"Neutropenia","ValueMeaning":{"publicId":"4291757","version":"1","preferredName":"Neutropenia","longName":"4291757","preferredDefinition":"A decrease in the number of neutrophils in the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neutropenia","conceptCode":"C80520","definition":"A decrease in the number of neutrophils in the peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8ABEA26-63D5-ED7C-E040-BB89AD4312B2","latestVersionIndicator":"Yes","beginDate":"2014-05-05","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-05-05","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56E9265-6BB3-60A8-E053-4EBD850A2CAD","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Monocytopenia","valueDescription":"Monocytopenia","ValueMeaning":{"publicId":"7519137","version":"1","preferredName":"Monocytopenia","longName":"7519137","preferredDefinition":"Abnormally low level of monocytes in the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monocytopenia","conceptCode":"C113714","definition":"Abnormally low level of monocytes in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56E9265-6BC1-60A8-E053-4EBD850A2CAD","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56E9265-6BDA-60A8-E053-4EBD850A2CAD","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Agammaglobulinemia","valueDescription":"Hypogammaglobulinemia","ValueMeaning":{"publicId":"4276835","version":"1","preferredName":"Hypogammaglobulinemia","longName":"4276835","preferredDefinition":"A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypogammaglobulinemia","conceptCode":"C26931","definition":"A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7A209D6-790C-98DB-E040-BB89AD4339B1","latestVersionIndicator":"Yes","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B945A415-6CD0-63CE-E053-4EBD850AEEBD","beginDate":"2021-01-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-01-19","modifiedBy":"ONEDATA","dateModified":"2021-01-19","deletedIndicator":"No"},{"value":"Poor response to tetanus / diphtheria antigens","valueDescription":"Tetanus And/Or Diphtheria Antigen Poor Response","ValueMeaning":{"publicId":"7519166","version":"1","preferredName":"Tetanus And/Or Diphtheria Antigen Poor Response","longName":"7519166","preferredDefinition":"A serious infectious disorder that follows wound contamination by the Gram-positive bacterium Clostridium tetani. The bacteria produce a neurotoxin called tetanospasmin, which causes muscle spasm in the jaw and other anatomic sites.: Used to indicate that either or both of two items or options may be valid.: A Gram-positive bacterial infection caused by Corynebacterium diphtheriae. It usually involves the oral cavity, pharynx, and nasal cavity. Patients develop pseudomembranes in the affected areas and manifest signs and symptoms of an upper respiratory infection. The diphtheria toxin may cause myocarditis, polyneuritis, and other systemic effects.: Any substance, generally a protein, that stimulates the immune system and elicits an immune response.  Recognition by the immune system elicits either a T-lymphocyte response, recognizing processed antigens, or a B-lymphocyte response, producing antibodies that bind to unprocessed antigens.: Of low value or worth.: Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tetanus","conceptCode":"C85185","definition":"A serious infectious disorder that follows wound contamination by the Gram-positive bacterium Clostridium tetani. The bacteria produce a neurotoxin called tetanospasmin, which causes muscle spasm in the jaw and other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Diphtheria","conceptCode":"C34541","definition":"A Gram-positive bacterial infection caused by Corynebacterium diphtheriae. It usually involves the oral cavity, pharynx, and nasal cavity. Patients develop pseudomembranes in the affected areas and manifest signs and symptoms of an upper respiratory infection. The diphtheria toxin may cause myocarditis, polyneuritis, and other systemic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Antigen","conceptCode":"C268","definition":"Any substance, generally a protein, that stimulates the immune system and elicits an immune response.  Recognition by the immune system elicits either a T-lymphocyte response, recognizing processed antigens, or a B-lymphocyte response, producing antibodies that bind to unprocessed antigens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Poor","conceptCode":"C77959","definition":"Of low value or worth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56EACBC-58D5-3EF6-E053-4EBD850AC389","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56EACBC-58EE-3EF6-E053-4EBD850AC389","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Poor response to Polysaccharide antigens","valueDescription":"Polysaccharide Antigen Poor Response","ValueMeaning":{"publicId":"7519167","version":"1","preferredName":"Polysaccharide Antigen Poor Response","longName":"7519167","preferredDefinition":"A large carbohydrate molecule. It contains many small sugar molecules that are joined chemically.: Any substance, generally a protein, that stimulates the immune system and elicits an immune response.  Recognition by the immune system elicits either a T-lymphocyte response, recognizing processed antigens, or a B-lymphocyte response, producing antibodies that bind to unprocessed antigens.: Of low value or worth.: Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polysaccharide","conceptCode":"C28179","definition":"A large carbohydrate molecule. It contains many small sugar molecules that are joined chemically.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Antigen","conceptCode":"C268","definition":"Any substance, generally a protein, that stimulates the immune system and elicits an immune response.  Recognition by the immune system elicits either a T-lymphocyte response, recognizing processed antigens, or a B-lymphocyte response, producing antibodies that bind to unprocessed antigens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Poor","conceptCode":"C77959","definition":"Of low value or worth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56EACBC-58FD-3EF6-E053-4EBD850AC389","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56EACBC-5916-3EF6-E053-4EBD850AC389","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"B-cell","valueDescription":"B-Lymphocyte","ValueMeaning":{"publicId":"2558266","version":"1","preferredName":"B-Lymphocyte","longName":"2558266","preferredDefinition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Lymphocyte","conceptCode":"C12474","definition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0A7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-9493-3B3A-E053-4EBD850AC272","beginDate":"2002-02-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Indeterminate","valueDescription":"Indeterminate","ValueMeaning":{"publicId":"2558963","version":"1","preferredName":"Indeterminate","longName":"2558963","preferredDefinition":"Cannot distinguish between two or more possible values in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate","conceptCode":"C48658","definition":"Cannot distinguish between two or more possible values in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B360-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-949D-3B3A-E053-4EBD850AC272","beginDate":"2002-02-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Mixed","valueDescription":"Mixed cells","ValueMeaning":{"publicId":"2559252","version":"1","preferredName":"Mixed cells","longName":"2559252","preferredDefinition":"Involving or composed of different kinds.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed","conceptCode":"C25259","definition":"Involving or composed of different kinds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cell","conceptCode":"C12508","definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B481-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-94A7-3B3A-E053-4EBD850AC272","beginDate":"2002-02-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Non-T/Non-B","valueDescription":"Non T-Lymphocyte / Non B-Lymphocyte","ValueMeaning":{"publicId":"2559573","version":"1","preferredName":"Non T-Lymphocyte / Non B-Lymphocyte","longName":"2559573","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.: An operation in which a term denies or inverts the meaning of another term or construction.: Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"B-Lymphocyte","conceptCode":"C12474","definition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5C2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-94B1-3B3A-E053-4EBD850AC272","beginDate":"2002-02-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-94BB-3B3A-E053-4EBD850AC272","beginDate":"2002-02-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"T-cell","valueDescription":"T-Lymphocyte","ValueMeaning":{"publicId":"2560141","version":"1","preferredName":"T-Lymphocyte","longName":"2560141","preferredDefinition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7FA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-94C5-3B3A-E053-4EBD850AC272","beginDate":"2002-02-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Mixed lineage ALL","valueDescription":"Mixed Lineage Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"5613389","version":"1","preferredName":"Mixed Lineage Acute Lymphoblastic Leukemia","longName":"5613389","preferredDefinition":"Involving or composed of different kinds.: Descent in a line from a common progenitor or source.: Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed","conceptCode":"C25259","definition":"Involving or composed of different kinds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lineage","conceptCode":"C60792","definition":"Descent in a line from a common progenitor or source.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"455A724B-BAB8-6A16-E053-F662850A11BF","latestVersionIndicator":"Yes","beginDate":"2017-01-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-94CF-3B3A-E053-4EBD850AC272","beginDate":"2017-01-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"AML","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"4263972","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"4263972","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1110-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-94D9-3B3A-E053-4EBD850AC272","beginDate":"2019-07-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Mixed Phenotype Acute Leukemia (MPAL)","valueDescription":"Mixed Phenotype Acute Leukemia","ValueMeaning":{"publicId":"7000422","version":"1","preferredName":"Mixed Phenotype Acute Leukemia","longName":"7000422","preferredDefinition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia","conceptCode":"C82179","definition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"950E57BC-8DF0-20B0-E053-F662850A4478","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-10-16","modifiedBy":"KUMMEROA","dateModified":"2023-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-94E3-3B3A-E053-4EBD850AC272","beginDate":"2019-10-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Hyper IgM","valueDescription":"Hyperimmunoglobulin M Syndrome","ValueMeaning":{"publicId":"7519095","version":"1","preferredName":"Hyperimmunoglobulin M Syndrome","longName":"7519095","preferredDefinition":"An immunodeficiency state characterized by very low serum IgG and IgA but either a normal or, more frequently, a markedly elevated concentration of polyclonal IgM.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperimmunoglobulin M Syndrome","conceptCode":"C3990","definition":"An immunodeficiency state characterized by very low serum IgG and IgA but either a normal or, more frequently, a markedly elevated concentration of polyclonal IgM.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56BB82F-94F6-3B3A-E053-4EBD850AC272","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-950F-3B3A-E053-4EBD850AC272","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Hyper IgE","valueDescription":"Hyperimmunoglobulin E Syndrome","ValueMeaning":{"publicId":"7519097","version":"1","preferredName":"Hyperimmunoglobulin E Syndrome","longName":"7519097","preferredDefinition":"A condition that is characterized by elevated serum IgE, dermatitis, and respiratory infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperimmunoglobulin E Syndrome","conceptCode":"C3144","definition":"A condition that is characterized by elevated serum IgE, dermatitis, and respiratory infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56BB82F-951C-3B3A-E053-4EBD850AC272","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-9535-3B3A-E053-4EBD850AC272","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"T decreased","valueDescription":"Reduced T-Lymphocyte","ValueMeaning":{"publicId":"7519098","version":"1","preferredName":"Reduced T-Lymphocyte","longName":"7519098","preferredDefinition":"Made less in size or amount or degree.: A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reduced","conceptCode":"C25640","definition":"Made less in size or amount or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56BB82F-9542-3B3A-E053-4EBD850AC272","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-955B-3B3A-E053-4EBD850AC272","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"T functional defect","valueDescription":"T-Lymphocyte Immunodeficiency due to Functional Defects","ValueMeaning":{"publicId":"7519099","version":"1","preferredName":"T-Lymphocyte Immunodeficiency due to Functional Defects","longName":"7519099","preferredDefinition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.: An indication that an immunodeficiency disorder is caused by the presence of immune cells that are dysfunctional.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunodeficiency due to Functional Defects","conceptCode":"C176669","definition":"An indication that an immunodeficiency disorder is caused by the presence of immune cells that are dysfunctional.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56BB82F-9565-3B3A-E053-4EBD850AC272","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"KUMMEROA","dateModified":"2021-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-957E-3B3A-E053-4EBD850AC272","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"NK functional defect","valueDescription":"Natural Killer Cell Immunodeficiency due to Functional Defects ","ValueMeaning":{"publicId":"7519100","version":"1","preferredName":"Natural Killer Cell Immunodeficiency due to Functional Defects ","longName":"7519100","preferredDefinition":"A type of immune cell that has granules (small particles) with enzymes that can kill tumor cells or cells infected with a virus. A natural killer cell is a type of white blood cell.: An indication that an immunodeficiency disorder is caused by the presence of immune cells that are dysfunctional.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Natural Killer Cell","conceptCode":"C12536","definition":"Natural killer cells are cells that resemble large granular lymphocytes.  They do not express markers of either T or B cell lineage. They are positive for CD16, CD56, and CD 94.  These cells do possess Fc receptors for IgG and can kill target cells using antibody-dependent cell-mediated cytotoxicity. They can also use perforin to kill cells in the absence of antibody and killing may occur without previous sensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunodeficiency due to Functional Defects","conceptCode":"C176669","definition":"An indication that an immunodeficiency disorder is caused by the presence of immune cells that are dysfunctional.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56BB82F-9588-3B3A-E053-4EBD850AC272","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"KUMMEROA","dateModified":"2021-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-95A1-3B3A-E053-4EBD850AC272","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Neutrophil functional defect","valueDescription":"Neutrophil Immunodeficiency due to Functional Defects","ValueMeaning":{"publicId":"7519101","version":"1","preferredName":"Neutrophil Immunodeficiency due to Functional Defects","longName":"7519101","preferredDefinition":"Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.: An indication that an immunodeficiency disorder is caused by the presence of immune cells that are dysfunctional.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neutrophil","conceptCode":"C12533","definition":"Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunodeficiency due to Functional Defects","conceptCode":"C176669","definition":"An indication that an immunodeficiency disorder is caused by the presence of immune cells that are dysfunctional.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56BB82F-95AB-3B3A-E053-4EBD850AC272","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"KUMMEROA","dateModified":"2021-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-95C4-3B3A-E053-4EBD850AC272","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"B functional defect","valueDescription":"B-Lymphocyte Immunodeficiency due to Functional Defects","ValueMeaning":{"publicId":"7519102","version":"1","preferredName":"B-Lymphocyte Immunodeficiency due to Functional Defects","longName":"7519102","preferredDefinition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.: An indication that an immunodeficiency disorder is caused by the presence of immune cells that are dysfunctional.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Lymphocyte","conceptCode":"C12474","definition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunodeficiency due to Functional Defects","conceptCode":"C176669","definition":"An indication that an immunodeficiency disorder is caused by the presence of immune cells that are dysfunctional.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56BB82F-95CE-3B3A-E053-4EBD850AC272","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"KUMMEROA","dateModified":"2021-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-95E7-3B3A-E053-4EBD850AC272","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"B decreased","valueDescription":"Reduced B-Lymphocyte","ValueMeaning":{"publicId":"7519103","version":"1","preferredName":"Reduced B-Lymphocyte","longName":"7519103","preferredDefinition":"Made less in size or amount or degree.: Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reduced","conceptCode":"C25640","definition":"Made less in size or amount or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"B-Lymphocyte","conceptCode":"C12474","definition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56BB82F-95F4-3B3A-E053-4EBD850AC272","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56BB82F-960D-3B3A-E053-4EBD850AC272","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56BB82F-947D-3B3A-E053-4EBD850AC272","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"KUMMEROA","dateModified":"2021-01-19","changeDescription":"2021-1-19 ak Added missing PV concepts. 2020-12-1 Versioned due to max length change and concepts added to existing PVs/additional PVs added per MC.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000449","version":"1","longName":"ALL Prev Untreated","context":"CTEP"},{"publicId":"2811795","version":"1","longName":"CLL Prev Untreated","context":"CTEP"}]},{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2670694","version":"1","longName":"Disease Relapse","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2812922","version":"1","longName":"Acute Leukemia Relapse","context":"NHLBI"},{"publicId":"2812925","version":"1","longName":"Fanconi Anemia Relapse","context":"NHLBI"},{"publicId":"2812927","version":"1","longName":"Myelodysplastic Syndrome (MDS) Relapse","context":"NHLBI"}]}],"AlternateNames":[{"name":"CCR","type":"USED_BY","context":"CCR"}],"ReferenceDocuments":[{"name":"Immunophenotype Lineage","type":"Preferred Question Text","description":"Immunophenotype Lineage","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Immunophenotype","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Immunophenotype lineage:","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Immunophenotype:","url":null,"context":"COG"},{"name":"Immune Phenotype","type":"Alternate Question Text","description":"Immune Phenotype","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56D44C0-88FD-365F-E053-4EBD850ADD30","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-01","modifiedBy":"KUMMEROA","dateModified":"2020-12-01","changeDescription":"2020-12-1 AK  Versioned due to using newer VD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}